natgillin/translations-raw huggingface dataset:
For active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by Streptococcus uberis, to reduce the somatic cell count in 
INDIKACIJA(E) Za aktivno imunizacijo zdravih krav in telic za zmanjšanje pojavnosti kliničnih intramamarnih okužb, ki jih povzroča Streptococcus uberis, in za zmanjšanje števila somatskih celic v vzorcih mleka z četrtin vimen pozitivnih na Streptococcus uberis, in za zmanjšanje izgub pri proizvodnji mleka, ki so posledica intramamarnih okužb, ki jih povzroča Streptococcus uberis.
Vaccinate only healthy animals. 
Posebni previdnostni ukrepi za uporabo pri živalih Cepite samo zdrave živali.
- First dose at approximately 60 days before the expected parturition date - Second dose at least 21 days before the expected parturition date - Third dose should be administered about 15 days after the calving. 
- drugi odmerek najmanj 21 dni pred predvidenim datumom telitve.
Montanide ISA ............................................................................................................................907.1 mg 
Montanid ISA ..............................................................................................................................907,1 mg Monofosforil lipid A (MPLA)
One dose (2 ml) contains: Lipoteichoic acid (LTA) from Biofilm Adhesion Component (BAC) of Streptococcus uberis, strain 
En odmerek (2 ml) vsebuje: lipoteihojska kislina (LTA) iz komponente lepljivega biofilma (Biofilm Adhesion Component - BAC) bakterije Streptococcus uberis, sev 5616 ................................................................... ≥ 1 RPU* *Enote relativne potence (ELISA)
A transient increase in rectal temperature (mean increase of 1°C but may be up to 2°C in individual animals) may very commonly occur in the first 24 hours after injection. 
(povprečno povečanje za 1 °C, pri določenih živalih je lahko tudi do 2 °C).
- Second dose at least 21 days before the expected parturition date - Third dose should be administered about 15 days after the calving. 
- tretji odmerek je treba aplicirati približno 15 dni po telitvi.
Cardboard box with 1 PET vial of 50 doses (100 ml). 
Kartonska škatla z 1 PET vialo s 50 odmerki (100 ml).
Cardboard box with 1 PET vial of 5 doses (10 ml). 
Kartonska škatla z 1 PET vialo s 5 odmerki (10 ml).
Cardboard box with 1 PET vial of 25 doses (50 ml). 
Kartonska škatla z 1 PET vialo s 25 odmerki (50 ml).
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 
A. PROIZVAJALEC BIOLOŠKE (BIOLOŠKIH) UČINKOVINE IN PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ
A transient increase in rectal temperature (mean increase of 1 °C but may be up to 2 °C in individual animals) may very commonly occur in the first 24 hours after injection. 
V prvih 24 urah po injekciji se zelo pogosto pojavi prehodno povečanje rektalne temperature
La Selva, 135 17170 Amer (Girona) Spain 
17170 Amer (Girona) Španija
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, applicants in the member states 
Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila,
Diclofenac ALTERGON 50 mg 
Diclofenac ALTERGON 50 mg 50 mg Tableta
After first opening: 7 months 
Po prvem odprtju: 7 mesecev.
Do not use after 7 months of first opening the bottle. 
Ne uporabljajte več kot 7 mesecev po prvem odprtju steklenice.
Then CLcr is adjusted for body surface area (BSA) as follows: 
CLcr je prilagojen na telesno površino (BSA - »body surface area«) na sledeč način:
Abnormal and aggressive behaviours 
Nenormalno in nasilno vedenje
It also contains maltitol liquid; patients with rare hereditary problems of fructose intolerance should not take this medicinal product. 
Vsebuje tudi raztopino maltitola; bolniki z redko prirojeno intoleranco za fruktozo ne smejo jemati tega zdravila.
• Close the bottle with the plastic screw cap. 
• Zaprite steklenico s plastično navojno zaporko.
If such behaviours are noticed, treatment adaptation or gradual discontinuation should be considered. 
Če so take spremembe vedenja opažene, je treba razmisliti o prilagoditvi zdravljenja ali postopni prekinitvi zdravljenja.
• Drink the whole contents of the glass/baby's bottle. 
• Popijte celotno vsebino kozarca/steklenice za hranjenje otrok.
Date of first authorisation: 29 September 2000 Date of latest renewal: 20 August 2015 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 29. september 2000 Datum zadnjega podaljšanja: 20. avgust 2015
• Abnormal thoughts, feeling irritable or reacting more aggressively than usually, or if you or your family and friends notice important changes in mood or behaviour. 
• Nenormalno razmišljanje, občutek razdraženosti ali bolj nasilno odzivanje, kot običajno, ali če vi ali vaša družina in prijatelji opazite pomembne spremembe razpoloženja ali vedenja.
Tell your doctor or pharmacist if any of the following side effects gets serious or last longer than a few days: 
Obvestite zdravnika ali farmacevta, če kateri koli od naslednjih neželenih učinkov postane resen ali traja dlje kot nekaj dni:
Dose and frequency 
odmerjanje in pogostnost
As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. 
Kot pri vseh drugih antiepileptikih se je treba nenadni prekinitvi uporabe levetiracetama izogniti, saj lahko to povzroči izbruh napadov, ki imajo lahko resne posledice za žensko in nerojenega otroka.
A doctor or a nurse will administer you Keppra as an intravenous infusion. 
Zdravnik ali medicinska sestra vam bodo zdravilo Keppra dali kot intravensko infuzijo.
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). 
Neželeni učinki so navedeni po padajoči resnosti in njihova pogostnost je opredeljena takole: zelo pogosti: (≥ 1/10); pogosti: (≥ 1/100 do < 1/10); občasni: (≥ 1/1.000 do < 1/100); redki: (≥ 1/10.000 do < 1/1.000) in zelo redki: (< 1/10.000).
Turn the bottle upside down (figure 5). 
Steklenico obrnite navzdol (slika 5).
NextPharma SAS, 17 Route de Meulan, F-78520 Limay, France. 
NextPharma SAS, 17 Route de Meulan, F-78520 Limay, Francija ali
* The colourants are: 
*Barvila so:
The following information is intended for healthcare professionals only: Directions for the proper use of Keppra is provided in section 3. 
Naslednje informacije so namenjene samo zdravstvenemu osebju: Navodila za pravilno uporabo zdravila Keppra se nahajajo v poglavju 3.
• Wash the syringe with water only (figure 8). 
• Sperite brizgo samo z vodo (slika 8).
• Turn the bottle the right way up (figure 6A). 
• Obrnite steklenico pokonci (slika 6A).
• Empty the contents of the syringe in a glass of water or baby's bottle by pushing the piston to the bottom of the syringe (figure 7). 
• Vsebino brizge spraznite v kozarec vode ali v steklenico za hranjenje otrok tako, da potisnete bat navzdol (slika 7).
• A small number of people being treated with anti-epileptics such as Keppra have had thoughts of harming or killing themselves. 
• pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je zdravilo Keppra, so se pojavile misli na samopoškodovanje ali samomor.
What Keppra is and what it is used for 
Kaj je zdravilo Keppra in za kaj ga uporabljamo
Keppra is for intravenous use. 
Zdravilo Keppra je za intravensko uporabo.
After measuring the correct dosage with an appropriate syringe, Keppra oral solution may be diluted in a glass of water or baby's bottle. 
Po tem, ko ste izmerili pravilen odmerek z ustrezno brizgo, lahko peroralno raztopino zdravila Keppra razredčite v kozarcu vode ali v steklenici za hranjenje otrok.
Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. 
Bolnike, zdravljene z levetiracetamom, je treba spremljati glede razvoja psihiatričnih znakov, ki kažejo na pomembne spremembe v razpoloženju in/ali spremembe osebnosti.
• Take the syringe and put it in the adaptor opening (figure 4). 
• Vzemite brizgo in jo dajte v odprtino adapterja (slika 4).
Keppra may impair your ability to drive or operate any tools or machinery, as it may make you feel sleepy. 
Zdravilo Keppra lahko oslabi vašo sposobnost vožnje ali upravljanja z orodjem ali stroji, saj lahko povzroči zaspanost.
Instructions for use: • Open the bottle: press the cap and turn it anticlockwise (figure 1) 
Navodila za uporabo: • Odprite steklenico: pritisnite zaporko in jo obrnite v nasprotni smeri urinega kazalca (slika1).
You should continue Keppra treatment for as long as your doctor has told you. 
Zdravljenje z zdravilom Keppra morate nadaljevati tako dolgo, kot vam je naročil zdravnik.
Should your doctor decide to stop your Keppra treatment, he/she will instruct you about the gradual withdrawal of Keppra. 
Če se bo vaš zdravnik odločil za prekinitev zdravljenja z zdravilom Keppra, vam bo dal napotke o postopni ukinitvi zdravila Keppra.
Levetiracetam may cause psychotic symptoms and behavioural abnormalities including irritability and aggressiveness. 
Levetiracetam lahko povzroči psihotične simptome in vedenjske spremembe, vključno z razdražljivostjo in agresivnostjo.
Date of opening only for the outer carton 
Datum odprtja (samo za škatlo)
These data are supplemented with the use of levetiracetam in corresponding openlabel extension studies, as well as post-marketing experience. 
Ti podatki so dopolnjeni s podatki iz ustreznih odprtih, razširjenih študij o uporabi levetiracetama ter s postmarketinškimi podatki.
Keppra oral solution also contains maltitol. 
Zdravilo Keppra peroralna raztopina vsebuje tudi maltitol.
Aluminium/PVC blister 
Aluminij/PVC pretisni omot
Swallow Keppra tablets with a sufficient quantity of liquid (e.g. a glass of water). 
Tablete zdravila Keppra zaužijte z dovolj tekočine (npr. s kozarcem vode).
Keppra must be administered twice a day, once in the morning and once in the evening, at about the same time each day. 
Zdravilo Keppra morate prejeti dvakrat na dan, enkrat zjutraj in enkrat zvečer, vsak dan ob približno istem času.
If discontinuation is considered, please refer to section 4.2. 
Če razmišljate o prekinitvi zdravljenja, glejte poglavje 4.2.
All other packs are available in standard aluminium/PVC blisters. 
Ostala pakiranja so na voljo v standardnih aluminij/PVC pretisnih omotih.
Remove the syringe from the adaptor (figure 6B). 
Odstranite brizgo iz adapterja (slika 6B).
Aesica Pharmaceuticals S.r.l., Via Praglia, 15, I-10044 Pianezza, Italy. 
Aesica Pharmaceuticals S.r.l., Via Praglia, 15, I-10044 Pianezza, Italija.
You may take Keppra with or without food. 
Zdravilo Keppra lahko vzamete s hrano ali brez.
It is therefore recommended to adjust the maintenance daily dose of Keppra, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2). 
Zato je priporočljivo dnevni vzdrževalni odmerek zdravila Keppra pri bolnikih z zmerno in hudo ledvično okvaro prilagoditi očistku kreatinina (glejte poglavje 4.2).
Insert the adaptor into the bottle neck (figure 3). 
Vstavite adapter v vrat steklenice (slika 3).
500 to 1,500 mg twice daily 500 to 1,000 mg twice daily 250 to 750 mg twice daily 250 to 500 mg twice daily 500 to 1,000 mg once daily 
500 do 1500 mg dvakrat na dan 500 do 1000 mg dvakrat na dan 250 do 750 mg dvakrat na dan 250 do 500 mg dvakrat na dan 500 do 1000 mg enkrat na dan(2)
Contains E216, E218 and maltitol liquid. 
SEZNAM POMOŽNIH SNOVI Vsebuje E216, E218 in raztopino maltitola.
Keppra is used: 
Zdravilo Keppra se uporablja:
You can switch from the film-coated tablets or from the oral solution to the intravenous formulation or reverse directly without dose adaptation. 
Prehod od filmsko obloženih tablet ali od peroralne raztopine k intravenski obliki ali obratno je lahko neposreden brez prilagajanja odmerka.
Other medicines and Keppra 
Druga zdravila in zdravilo Keppra
Dose and frequency (1) Infants 1 to less than 6 months 
odmerjanje in pogostnost(1) Dojenčki od 1 do manj kot 6 mesecev
The recommended dose must be diluted in at least 100 ml of a compatible diluent and infused over 15-minutes. 
Priporočen odmerek se mora razredčiti v vsaj 100 ml kompatibilnega topila in infundirano 15 minut.
• convulsion, balance disorder (equilibrium disorder), dizziness (sensation of unsteadiness),lethargy (lack of energy and enthusiasm), tremor (involuntary trembling); 
• konvulzije, motnje ravnotežja, omotica (občutek nesigurnosti), letargija (pomanjkanje energije in navdušenja), tremor (nehoteno tresenje)
In all of the above cases Keppra oral solution should be used. 
V vseh teh primerih se mora uporabiti zdravilo Keppra peroralna raztopina.
Since there was limited exposure for Keppra intravenous use and since oral and intravenous formulations are bioequivalent, the safety information of Keppra intravenous will rely on Keppra oral use. 
Zaradi omejene izpostavljenosti zdravila Keppra za intravensko uporabo in bioekvivalence med peroralno in intravensko obliko se informacije o varnosti za zdravilo Keppra za intravensko uporabo navezujejo na zdravilo Keppra za peroralno uporabo.
Keppra concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute intravenous infusion (see section 6.6). 
Koncentrat zdravila Keppra je samo za intravensko uporabo, priporočeni odmerek mora biti razredčen v vsaj 100 ml kompatibilnega topila in uporabljen intravensko kot 15 -minutna intravenska infuzija (glejte poglavje 6.6).
Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behavior Checklist). 
Rezultati, povezani z vedenjskimi in emocionalnimi funkcijami, kažejo pri bolnikih, ki se zdravijo z levetiracetamom, poslabšanje agresivnega obnašanja, ki se izmeri na standardiziran in sistematičen način z uporabo validiranega merskega instrumenta (CBCL - Achenbach Child Behavior Checklist).
UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. 
UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgija Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
For doctors and nurses, more detailed direction for the proper use of Keppra is provided in section 6. 
Za zdravnike in medicinske sestre so podrobna navodila za uporabo zdravila Keppra navedena v poglavju 6.
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of -ethyl-2-oxo-1pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances. 
Zdravilna učinkovina levetiracetam je pirolidonski derivat (S-enantiomer -etil-2-okso-1pirolidinacetamida), ki kemično ni podoben drugim protiepileptičnim učinkovinam.
• If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in Section 6). 
• če ste alergični na levetiracetam, pirolidonske derivate ali katero koli sestavino tega zdravila
• Keppra is used as a chronic treatment. 
• Zdravilo Keppra se uporablja za dolgotrajno zdravljenje.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 
Razdelilna zareza je namenjena le delitvi tablete za lažje požiranje in ne delitvi na dva enaka odmerka.
Duration of treatment There is no experience with administration of intravenous levetiracetam for longer period than 4 days. 
Trajanje zdravljenja • Ni izkušenj z intravensko uporabo levetiracetama za obdobje daljše od 4 dni.
Keppra concentrate for solution for infusion is an alternative for patients when administration of the antiepileptic oral Keppra medicine is temporarily not feasible. 
Zdravilo Keppra koncentrat za raztopino za infundiranje je alternativa za bolnike, ko uporaba peroralnega protiepileptičnega zdravila Keppra začasno ni mogoča.
Keppra concentrate is an alternative for patients when oral administration is temporarily not feasible. 
Koncentrat zdravila Keppra je alternativa za bolnike, pri katerih peroralna uporaba začasno ni mogoča.
43.6 % of the levetiracetam treated patients and 19.6 % of the patients on placebo were considered as responders. 
43,6 % bolnikov, ki so se zdravili z levetiracetamom, in 19,6 % bolnikov, ki so prejemali placebo, se je na zdravljenje odzvalo.
• Dextrose 50 mg/ml (5%) solution for injection 
• dekstroza 50 mg/ml (5 %) raztopina za injiciranje
Only limited evidence is available on the neurodevelopment of children exposed to Keppra monotherapy in utero. 
O nevrološkem razvoju otrok, ki so bili in utero izpostavljeni zdravilu Keppra, uporabljenim samostojno, so na voljo samo omejeni dokazi.
Oral contraceptives and other pharmacokinetics interactions Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. 
Peroralni kontraceptivi in druge farmakokinetične interakcije Levetiracetam v odmerku 1000 mg na dan ni vplival na farmakokinetiko peroralnih kontraceptivov (etinilestradiola in levonorgestrela); endokrini parametri (luteinizirajoči hormon in progesteron) se niso spremenili.
The starting dose for a child or adolescent of 25kg should be 250mg twice daily with a maximum dose of 750mg twice daily. 
Začetni odmerek za otroka ali mladostnika, težkega 25 kg, je 250 mg dvakrat na dan z največjim odmerkom 750 mg dvakrat na dan.
This presentation should be prescribed for children aged 4 years and older, adolescents and adults. 
To pakiranje predpišemo otrokom, starim 4 leta in več, mladostnikom in odraslim.
It was concluded that Keppra was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. 
Ugotovili so, da se zdravilo Keppra pri populaciji po protokolu ne razlikuje (ni manjvredno) od placeba glede spremembe od začetnih vrednosti rezultatov testiranja spomina in pozornosti (Leiter-R Attention and Memory, Memory Screen Composite).
The 100 x 1 tablet packs are available in aluminium/PVC perforated unit dose blisters. 
Pakiranje 100 x 1 tableta je na voljo v aluminij/PVC perforiranih pretisnih omotih za enkratni odmerek.
Intermediate packaging containing 100 tablets for box of 200 (2 x 100) tablets without blue box 
Vmesno pakiranje, ki vsebuje 100 tablet, za škatlo z 200 (2 x 100) tabletami brez modrega okenca
For the full list of excipients, see section 6.1. 
Za celoten seznam pomožnih snovi glejte poglevje 6.1.
• on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. 
• samostojno za zdravljenje pri odraslih in mladostnikih od 16. leta starosti z na novo diagnosticirano epilepsijo, za zdravljenje določene oblike epilepsije.
Example: if your daily dose is 1000 mg, your reduced starting dose is 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening. 
Na primer: če je vaš dnevni odmerek 1000 mg,je vaš zmanjšan začetni odmerek 2 tableti po 250 mg zjutraj in 2 tableti po 250 mg zvečer.
A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation). 
Pri odraslih in otrocih so ugotovili pomembno povezavo med koncentracijo v plazmi in slini (razmerje koncentracij v slini/plazmi se giblje med 1 in 1,7 za tableto in za peroralno raztopino 4 ure po odmerku).
The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness.The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. 
Neželeni učinki, o katerih so najpogosteje poročali, so bili nazofaringitis, somnolenca, glavobol, utrujenost in omotica.Profil neželenih učinkov, ki je opisan spodaj, temelji na analizi združenih s placebom nadzorovanih kliničnih preskušanj za vse preučevane indikacije, v katerih so z levetiracetamom zdravili 3416 bolnikov.
In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and βcarbolines. 
Poleg tega delno preprečuje inhibicijo GABA in glicinskih kanalčkov, povzročeno z Zn2+ in β- karbolini.
Keppra tablets are packaged in blister packs supplied in cardboard boxes containing: 
Zdravilo Keppra tablete je na voljo v pretisnih omotih, ki so pakirani v škatle po:
Keppra therapy can be initiated with either intravenous or oral administration. 
Zdravljenje z zdravilom Keppra lahko začnemo z intravensko ali peroralno uporabo.
• Separate the adaptor from the syringe (figure 2). 
• Ločite adapter od brizge (slika 2).
Excipients Keppra 750 mg film-coated tablets contain E110 colouring agent which may cause allergic reactions. 
Zdravilo Keppra 750 mg filmsko obložene tablete vsebuje barvilo E110, ki lahko povzroči alergijske reakcije.
General dose: Keppra is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml (500mg) and 15 ml (1500mg). 
Običajni odmerek: zdravilo Keppra se jemlje dvakrat na dan, razdeljen na dva enaka odmerka, vsak posamezen odmerek znaša med 5 ml (500 mg) in 15 ml (1500 mg).
Paediatric population The tablet formulation is not adapted for use in infants and children under the age of 6 years. 
Pediatrična populacija Farmacevtska oblika tableta ni prilagojena za uporabo pri dojenčkih in otrocih, mlajših od 6 let.
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95 % CI: -7.8 8.2). 
73,0 % bolnikov, ki so se zdravili z levetiracetamom, in 72,8 % bolnikov, ki so se zdravili s karbamazepinom z nadzorovanim sproščanjem (CR), je bilo šest mesecev brez napadov; prilagojena absolutna razlika med zdravljenjema je bila 0,2 % (95 % CI: 7,8-8,2).
In order to ensure the accuracy of the dosing, this presentation should be prescribed for infants and young children aged from 6 months to less than 4 years. 
Da zagotovimo točnost odmerjanja moramo pri dojenčkih in mlajših otrocih, starih od 6 mesecev do manj kot 4 leta, predpisati to pakiranje.
The oral solution may be diluted in a glass of water or baby's bottle and may be taken with or without food. 
Raztopina za peroralno uporabo se lahko raztopi v kozarcu vode ali steklenici za hranjenje otrok.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, noninferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. 
Učinkovitost levetiracetama za samostojno zdravljenje je bila dokazana v dvojno slepi študiji z vzporednimi skupinami, ki dokazuje, da levetiracetam po učinkovitosti ni nič slabši od karbamazepina z nadzorovanim sproščanjem (CR), pri 576 bolnikih, starih 16 let ali več, z na novo ali nedavno diagnosticirano epilepsijo.
UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium or 
UCB Pharma SA, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgija ali
Keppra 250 mg film-coated tablets Keppra 500 mg film-coated tablets Keppra 750 mg film-coated tablets Keppra 1000 mg film-coated tablets 
Keppra 250 mg filmsko obložene tablete Keppra 500 mg filmsko obložene tablete Keppra 750 mg filmsko obložene tablete Keppra 1000 mg filmsko obložene tablete levetiracetam